NCT03505528View on ClinicalTrials.gov

An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

October 30, 2019

Study Completion Date

October 30, 2019

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Nanoparticle albumin-bound paclitaxel

Abraxane is administered intravenous at a constant dose of 100mg/m2

DRUG

Phenelzine Sulfate

Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d

Trial Locations (3)

260

Canberra Region Cancer Centre, Canberra

2170

Liverpool Cancer Therapy Centre, Sydney

2500

Southern Medical Day Care Centre, Wollongong

Sponsors
All Listed Sponsors
collaborator

The Canberra Hospital

OTHER

collaborator

Southern Medical Day Care Centre

UNKNOWN

collaborator

Liverpool Cancer Therapy Centre

OTHER_GOV

lead

EpiAxis Therapeutics

INDUSTRY

NCT03505528 - An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer | Biotech Hunter | Biotech Hunter